ArticleAmerican journal of translational research2026
The impact of anti-vascular endothelial growth factor therapy on the activation status of retinal macrophages/microglia in patients with diabetic retinopathy and familial exudative vitreoretinopathy and its association with treatment response.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the impact of anti-vascular endothelial growth factor (anti-VEGF) therapy on retinal macrophage/microglial activation in patients with diabetic retinopathy (DR) and familial exudative vitreoretinopathy (FEVR), and to assess its association with treatment response.
methodsThis single-center retrospective cohort study included 122 eyes in DR patients and 135 eyes in FEVR patients who received at least three intravitreal anti-VEGF injections between January 2018 and June 2025. Intraretinal hyperreflective foci (IRH) on optical coherence tomography (OCT) were used as an imaging surrogate for microglial activation, and aqueous humor levels of inflammatory cytokines (interleukin-1β [IL-1β], tumor necrosis factor-α [TNF-α], and interleukin-10 [IL-10]) were measured. At 6 months post-treatment, responders were defined as those achieving both a ≥20% reduction in central retinal thickness (CRT) and an improvement of ≥5 ETDRS letters in best-corrected visual acuity (BCVA). Spearman correlation and multivariate logistic regression analyses were performed.
resultsBaseline IRH counts were significantly higher in the DR group than in the FEVR group (17.37±4.99 vs. 9.56±3.33, P < 0.001). After 6 months of treatment, IRH numbers decreased significantly in both groups (both P < 0.001), with responders showing a greater reduction in IRH (ΔIRH) than non-responders (both P < 0.001). Baseline IRH was positively correlated with the magnitude of CRT reduction (ΔCRT; r = 0.294, P = 0.003). In multivariate analysis, after adjusting for potential confounders, baseline IRH emerged as an independent predictor of treatment response (OR = 1.923, 95% CI: 1.314-2.825, P = 0.002). In the DR subgroup, higher glycated hemoglobin (HbA1c) level was also a significant negative predictor of response (OR = 0.752, 95% CI: 0.613-0.924, P = 0.028).
conclusionsAnti-VEGF therapy effectively suppresses retinal macrophage/microglial activation in both DR and FEVR. The degree of activation suppression is closely linked to treatment response, suggesting that baseline IRH may serve as a non-invasive biomarker for predicting anti-VEGF efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.